National Comprehensive Cancer Network 2020 guidelines: criteria for discontinuation of tyrosine kinase inhibitor therapy
| TKI discontinuation may be considered if all criteria below are met . |
|---|
| Age ≥18 y |
| CP-CML, no history of accelerated or blast phase CML |
| Quantifiable BCR-ABL1 transcripts |
| TKI therapy for ≥3 y |
| Stable MR4 for ≥2 y |
| Access to real time quantitative polymerase chain reaction with sensitivity of at least MR4.5 |
| TKI discontinuation may be considered if all criteria below are met . |
|---|
| Age ≥18 y |
| CP-CML, no history of accelerated or blast phase CML |
| Quantifiable BCR-ABL1 transcripts |
| TKI therapy for ≥3 y |
| Stable MR4 for ≥2 y |
| Access to real time quantitative polymerase chain reaction with sensitivity of at least MR4.5 |
CML, chronic myeloid leukemia; CP, chronic phase; MR4.5, 4.5-log molecular response; TKI, tyrosine kinase inhibitor.